CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms

Document Type : Research Articles


1 Clinical Pathology Department, Faulty of Medicine, Cairo University, Egypt.

2 Clinical Oncology Department (NEMROCK), Cairo University, Egypt.

3 Clinical Pathology Department, National Cancer Institute (NCI), Cairo University, Egypt.


Background: Multiparameter flow cytometry is a useful tool for diagnostic evaluation of mature B-cell neoplasms
(MBN). Recently, it has been shown that assessment of CD200 expression may improve the distinction between
chronic lymphocytic leukemia (CLL; CD200 positive) and mantle cell lymphoma (MCL; CD200 negative), but any
potential as a prognostic marker for CLL remains to be established. Materials and methods: This cross sectional
study was conducted on sixty-seven patients newly diagnosed as having mature B-cell lymphoproliferative disorders
Levels of CD 200 in lymphoma cells were assessed. Results: CD200 was consistently expressed in CLL and hairy
cell leukemia B cells, but not in MCL cells. Heterogeneous expression was noted in other CD5 positive Non-Hodgkin
lymphomas. High CD200 expression (≥50%) was associated with a higher CD5, 19 and CD23 expression, older
age, higher TLC and absolute lymphocyte count, hepatomegaly, splenomegaly and a higher Rai stage. There were
no significant correlations between CD200 expression and response to treatment. Conclusion: CD200 could be of high
value in distinguishing CLL, MCL, and atypical CLL. CD200 expression can also be of prognostic and therapeutic
value in CLL cases.


Main Subjects